Teva’s Ecopipam NDA Looks Like a Pipeline Win. The Commercial Math Is More Complicated.
Teva filed an NDA for ecopipam, a first-in-class pediatric Tourette therapy, but orphan drug status and $15B in debt...
Teva Pharmaceuticals
The Junk-to-Grade Playbook: Why Teva’s Upgrade Is a Signal, Not a Story
Teva's BBB- upgrade from Fitch on May 18 signals a new M&A-ready posture—and reveals a playbook other over-leveraged pharma...
Late-Stage or Nothing: How Big Pharma Is Rewriting the M&A Playbook One NDA Away From Filing
Teva's $900M Emalex deal for NDA-ready ecopipam in Tourette syndrome signals a pharma M&A shift: buy at Phase 3...